Buy BPC-157 Online | Research-Grade Pentadecapeptide ≥99% Purity

Buy BPC-157 Online from SourceTides and receive a research-grade pentadecapeptide supplied at ≥99% purity, confirmed by reverse-phase HPLC and third-party mass spectrometry on every production batch. BPC-157 — formally catalogued as Body Protection Compound-157, and also referenced in the scientific literature as Bepecin, PL 14736, and PL-10 — is a synthetic 15-amino-acid peptide derived from a gastroprotective sequence isolated from human gastric juice. It was first characterised scientifically in 1993 by Sikirić and colleagues and has since generated one of the most extensive preclinical peptide research bodies in modern biomedical science, spanning gut integrity, musculoskeletal repair, wound healing, angiogenesis, and neurotransmitter modulation.

Every vial of BPC-157 dispatched by SourceTides ships with a batch-specific Certificate of Analysis (CoA) and is handled under cold-chain packaging conditions from production facility to your laboratory. This product is supplied exclusively for in-vitro and laboratory research purposes only and is not approved by the FDA, EMA, or any regulatory authority for human or veterinary therapeutic use.

BPC-157 Research Peptide — Full Technical Specifications

The table below consolidates the key physicochemical and logistical parameters researchers need before sourcing BPC-157 for a study protocol.

What Is BPC-157? Origins, Structure and Science

BPC-157 is a synthetic partial sequence of the naturally occurring body protection compound (BPC) — a gastroprotective protein present in human gastric juice. The intact parent protein has long been recognised for its role in protecting and maintaining the integrity of the gastrointestinal mucosa. What makes BPC-157 scientifically distinctive is that it represents the specific 15-amino-acid fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that researchers isolated, synthesised in pure form, and began systematically evaluating in preclinical models from the early 1990s onward.

Unlike the parent BPC protein, BPC-157 in this isolated synthetic form does not occur naturally in the body. Scientists synthesised this fragment specifically because of its remarkable chemical stability: it resists enzymatic degradation, remains intact in human gastric juice for more than 24 hours — a property almost unheard of in peptide research — and is bioavailable via multiple administration routes studied in animal models. Its CAS number 137525-51-0 and molecular weight of approximately 1,419 Daltons are consistent across the peer-reviewed literature. (Wikipedia — BPC-157 chemical identity)

The comprehensive 2025 review by Jóźwiak et al. published in MDPI Pharmaceuticals describes BPC-157 as exhibiting “pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders,” alongside what the authors characterise as a “desirable safety profile” in the animal and limited human case data reviewed. (PMC — Jóźwiak et al. 2025, MDPI Pharmaceuticals)

BPC-157 Mechanism of Action — How It Works at the Cellular Level

BPC-157 does not operate through a single receptor pathway. It engages several overlapping biological systems simultaneously, which is one reason it has attracted interest across such diverse research domains. The following section outlines the primary mechanistic pathways characterised in peer-reviewed preclinical literature.

Nitric Oxide (NO) System Modulation

The most consistently documented mechanism across BPC-157 studies is its interaction with the nitric oxide system. BPC-157 has been shown to counteract the effects of NO synthase (NOS) inhibitors such as L-NAME while also modulating NO production in tissue-specific ways that support vascular function, mucosal cytoprotection, and wound healing. This dual NO modulation appears central to its effects on both GI tissue protection and peripheral tissue repair. (MDPI Pharmaceuticals 2025 — NO system review)

Growth Hormone Receptor (GHR) Upregulation

A landmark study published in PMC (Chang et al.) demonstrated that BPC-157 dose- and time-dependently increased the expression of growth hormone receptor (GHR) in tendon fibroblasts at both the mRNA and protein levels, as confirmed by RT/real-time PCR and Western blot analysis. This GHR upregulation sensitises tendon cells to circulating growth hormone, amplifying downstream proliferative signalling. This finding provides a concrete mechanistic explanation for BPC-157’s repeatedly observed effects on tendon fibroblast proliferation and connective tissue repair. (PMC — BPC-157 GHR expression in tendon fibroblasts)

FAK-Paxillin Pathway and Fibroblast Migration

Studies examining the Journal of Applied Physiology (Chang et al., 2011) showed BPC-157 markedly increased the in-vitro migration of tendon fibroblasts in a dose-dependent manner via transwell filter assay, while also significantly improving cell survival under oxidative stress (H₂O₂ challenge). The FAK-paxillin signalling axis — critical for focal adhesion assembly, cytoskeletal organisation, and directional cell migration during tissue repair — is engaged by BPC-157 as part of this pro-migratory, pro-survival effect. (Journal of Applied Physiology — BPC-157 tendon fibroblast migration)

Angiogenesis — Proangiogenic Activity

BPC-157 consistently promotes angiogenesis (new blood vessel formation) in wound and tissue repair models. This proangiogenic effect is mechanistically linked to VEGF pathway upregulation and direct endothelial cell stimulation. In musculoskeletal injury models, BPC-157-treated tissues showed measurably increased vascular density compared to controls, which is significant because tendon and cartilage are poorly vascularised tissues where repair capacity is inherently limited by blood supply. The 2025 systematic review in HSS Journal (Vasireddi et al., covering 36 studies) confirmed this angiogenic pattern across multiple tissue types. (Sage — Vasireddi et al. 2025 systematic review)

ERK1/2 Signalling and Endothelial Repair

The 2025 narrative review by McGuire et al. (University of Utah, Current Reviews in Musculoskeletal Medicine, PubMed Dec 2025) notes that BPC-157 engages ERK1/2 signalling — a major cell-survival and proliferation cascade — to facilitate endothelial and muscle repair, alongside its anti-inflammatory effects. This positions BPC-157 as acting at the intersection of vascular biology and musculoskeletal regeneration. (PubMed — McGuire et al. 2025 narrative review)

Antioxidant and Free Radical Scavenging

BPC-157 demonstrates antioxidant activity through stabilisation of free radical scavengers and attenuation of oxidative stress-induced lesions. The MDPI 2025 review identifies this antioxidant capacity as relevant to potential protective effects in neurological disease models, where oxidative stress is a known contributing factor. This also explains the enhanced cell survival observed in the in-vitro H₂O₂ challenge studies.

Collagen and Myotendinous Junction Remodelling

BPC-157 studies in transected muscle models consistently show abundant longitudinally-oriented collagen fibre formation at repair sites, mirroring the collagen architecture seen in successfully healed tendons. At the myotendinous junction specifically — a common site of sports injury — BPC-157 appears to coordinate collagen fragment orientation, vascular density restoration, and NO system activity to support structural repair even under conditions of corticosteroid-induced healing impairment. (PMC — BPC-157 myotendinous junction therapy)

BPC-157 Preclinical Research Areas — Evidence Summary Table

The following table maps the major research domains, the specific preclinical model types examined, proposed mechanisms, and relevant peer-reviewed source links. All data is from animal or in-vitro models. Human clinical evidence remains limited.

All data above is derived exclusively from preclinical (animal/in-vitro) studies. No FDA-approved human therapeutic indications exist for BPC-157.

BPC-157 for Musculoskeletal Research — 2025 Systematic Review Findings

The 2025 systematic review by Vasireddi, Hahamyan, Salata, Karns, Calcei, Voos, and Apostolakos — published in the peer-reviewed Orthopaedic Journal of Sports Medicine (Sage Publications) — represents the most comprehensive synthesis of BPC-157’s musculoskeletal literature to date. The authors searched PubMed, Cochrane, and Embase from database inception to June 2024, ultimately reviewing 36 studies (35 preclinical, 1 clinical). Their findings confirmed that BPC-157 improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injury models in animal research. The authors noted BPC-157 promotes healing by boosting growth factors and reducing inflammation, with broad tissue-type applicability that distinguishes it from more tissue-specific repair compounds. (Sage — Vasireddi et al. 2025 full study)

A complementary 2025 narrative review from the University of Utah’s Department of Physical Medicine and Rehabilitation (McGuire, Martinez, Lenz, Skinner, Cushman; Current Reviews in Musculoskeletal Medicine, December 2025) further characterised BPC-157 as a synthetic pentadecapeptide with regenerative properties demonstrated across numerous animal models, engaging ERK1/2 signalling, promoting endothelial and muscle repair, and exerting anti-inflammatory effects that support angiogenesis, fibroblast activity, and neuromuscular stabilisation — particularly in poorly vascularised tissues. (PubMed — McGuire et al. 2025)

BPC-157 Gastric and Gut Health Research

BPC-157’s origins as a fragment of a gastric juice protein make its GI research particularly mechanistically coherent. Preclinical studies have examined its role in multiple gut injury models including gastric ulceration, intestinal anastomosis, oesophageal injury, inflammatory bowel disease (IBD) models, and colon perforation. A comprehensive 2024 review documented positive outcomes across numerous intestinal anastomosis and fistula models, with BPC-157 accelerating wound closure and promoting mucosal healing across GI tissue types. (MDPI Pharmaceuticals 2025 — full multifunctionality review)

The peptide’s unusual resistance to gastric acid and proteolytic enzymes — intact for more than 24 hours in human gastric juice — is directly relevant to oral administration models in GI research protocols. This stability profile has made it a subject of interest for researchers studying conditions where peptide delivery through the oral route is otherwise pharmacokinetically impractical. Most peptides degrade rapidly in gastric conditions; BPC-157’s structural resilience is a defining characteristic that sets it apart as a study compound.

BPC-157 Pharmacokinetics — Absorption, Distribution, Metabolism and Excretion

The 2022 study published in Frontiers in Pharmacology by Wang and colleagues conducted the most comprehensive ADME characterisation of BPC-157 to date, using both rat and beagle dog models across intravenous and intramuscular administration routes. This study is essential reading for any researcher designing a BPC-157 dosing protocol.

Key pharmacokinetic findings from this study include: following single IV administration, the elimination half-life (t½) in rats averaged 15.2 minutes, with rapid systemic clearance (AUC₀₋ₜ of 399 ng·min/mL). After intramuscular dosing at 20, 100, and 500 μg/kg, peak concentration (Cmax) was reached at Tmax of 3 minutes across all doses, with Cmax values of 12.3, 48.9, and 141 ng/mL respectively — confirming linear pharmacokinetics across this dose range. The mean absolute IM bioavailability was 14–19% in rats and 45–51% in beagle dogs. Primary excretory routes were urine and bile. No visual signs of toxicity were observed and no sex-based difference in plasma concentration was detected. (PMC — Frontiers in Pharmacology 2022, ADME BPC-157)

Source: Wang et al., Frontiers in Pharmacology 2022. All data from preclinical models only.

High-Purity BPC-157 for Sale — SourceTides Quality Control Standards

When researchers buy BPC-157 online, purity and traceability are non-negotiable variables. Impure peptide preparations introduce confounding variables that invalidate experimental results and waste resources. SourceTides addresses this through a multi-stage quality control process applied to every production batch before any vial is released for sale.

BPC-157 Regulatory and Legal Status — 2025 Overview

Understanding the regulatory status of BPC-157 across jurisdictions is critical before ordering. The landscape is not uniform and has evolved over 2022–2025:

Researchers are solely responsible for verifying that ordering and using BPC-157 complies with all applicable laws and regulations in their jurisdiction. View SourceTides’ full shipping and compliance policy.

Buy BPC-157 Online vs. Other Research Peptides — Side-by-Side Comparison

Researchers selecting peptides for healing, repair, or regeneration protocols often evaluate BPC-157 alongside related compounds. The table below provides a factual comparison to assist in protocol design.

BPC-157 Peer-Reviewed Research References — Full Citation Table

Frequently Researched Alongside BPC-157 — SourceTides Catalogue

Researchers studying BPC-157 commonly design multi-peptide protocols or explore complementary research compounds. Browse the full SourceTides research peptide catalogue for related compounds:

• TB-500 (Thymosin Beta-4) — Actin regulation & tissue remodelling research — frequently studied alongside BPC-157 in musculoskeletal repair models
• Sermorelin — Growth hormone secretagogue research
• CJC-1295 — Long-acting GH analog research peptide
• Ipamorelin — Selective GH secretagogue research, minimal off-target signalling
• Browse All Research Peptides — SourceTides full catalogue
• SourceTides Peptide Research Guide — Protocol design & reference resources

Frequently Asked Questions — Buy BPC-157 Online